<DOC>
	<DOC>NCT02918019</DOC>
	<brief_summary>This is a Phase IIb, randomized, placebo-controlled, double-blind, multicenter, multi-arm study will evaluate efficacy, safety, and pharmacokinetic of MSTT1041A compared with placebo as add-on therapy in participants with severe, uncontrolled asthma who are receiving medium- or high-dose inhaled corticosteroid (ICS) therapy and at least one of the following additional controller medications: long-acting beta-agonists (LABA), leukotriene modifier (LTM), long-acting muscarinic antagonist (LAMA), or long-acting theophylline preparation. The total duration of this study for each participant is approximately 70 weeks including screening, run-in, treatment, and follow-up.</brief_summary>
	<brief_title>A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Body mass index (BMI) of 18 to 35 kilogram/square meter (kg/m^2) and weight &gt;= 40 kg at screening Documented physiciandiagnosed asthma On high dose inhaled corticosteroid (ICS) therapy plus at least one additional allowed controller medication Forced expiratory volume in 1 second (FEV1) of 40% to 80% of predicted Evidence of uncontrolled asthma Use of contraceptive measures Diagnosis of mimics of asthma Diagnosis of occupational asthma, aspirinsensitive asthma, asthma chronic obstructive pulmonary disease overlap syndrome, or bronchiolitis, as determined by the investigator Pregnant or lactating, or intending to become pregnant during the study or within 20 weeks after the last dose of MSTT1041A Recent history of smoking History or evidence of substance abuse that would pose a risk to patient safety, interfere with the conduct of the study, have an impact on the study results Asthma exacerbation within 4 weeks prior to screening Intubation for respiratory failure due to asthma within 12 months prior to screening Comorbid conditions that may interfere with evaluation of investigational medicinal product Known sensitivity to any of the active substances or their excipients to be administered during dosing Positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>